Cargando…

Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)

Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Abdullah Mahmood, BenMohamed, Fatima, Decina, Alessandra, Mukherjee, Sanjay, Levi, Shelley, Garrido Castillo, Laura Nalleli, Bréchot, Davide, Jurcic, Joseph, Raza, Azra, Paterlini Bréchot, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267270/ https://www.ncbi.nlm.nih.gov/pubmed/37316755 http://dx.doi.org/10.1007/s12032-023-02064-z

Ejemplares similares

Polyploid Giant Cancer Cells Are Frequently Found in the Urine of Prostate Cancer Patients
por: Garrido Castillo, Laura Nalleli, et al.
Publicado: (2023)

Predictive Value of Circulating Tumor Cells Detected by ISET(®) in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy
por: Garrido Castillo, Laura Nalleli, et al.
Publicado: (2022)

Circulating Tumor Cells: Who is the Killer?
por: Paterlini-Bréchot, Patrizia
Publicado: (2014)

Circulating Tumor Cells for the Management of Renal Cell Carcinoma
por: Broncy, Lucile, et al.
Publicado: (2018)

Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer
por: Broncy, Lucile, et al.
Publicado: (2019)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
por: Raza, Azra, et al.
Publicado: (2020)

Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion
por: Laget, Sophie, et al.
Publicado: (2017)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Serca1 Truncated Proteins Unable to Pump Calcium Reduce the Endoplasmic Reticulum Calcium Concentration and Induce Apoptosis
por: Chami, Mounia, et al.
Publicado: (2001)

The biology of myelodysplastic syndromes: unity despite heterogeneity
por: Raza, Azra, et al.
Publicado: (2010)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia
por: Ewalt, M, et al.
Publicado: (2011)

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
por: Wesa, Kathleen M., et al.
Publicado: (2014)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
por: Yao, Chi-Yuan, et al.
Publicado: (2016)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

AlphaFold, small-angle X-ray scattering and ensemble modelling: a winning combination for intrinsically disordered proteins
por: Receveur-Bréchot, Véronique
Publicado: (2023)

Frequent Frauds Found in Governments and Not-for-Profits
por: Dennis, Lynda
Publicado: (2018)

Two different “tales” of ATG7: Clinical relevance to myelodysplastic syndromes
por: Ali, Abdullah M., et al.
Publicado: (2016)

Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).
por: Sozzi, G., et al.
Publicado: (1990)

Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population
por: Du, Meng-yi, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma
por: Broncy, Lucile, et al.
Publicado: (2018)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tcc06p5pqcaefnr21ho4jdlav